Mechanisms of Pathological Spread of Abnormal Proteins in LBD and FTD (R01 Clinical Trial Not Allowed)

The summary for the Mechanisms of Pathological Spread of Abnormal Proteins in LBD and FTD (R01 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Mechanisms of Pathological Spread of Abnormal Proteins in LBD and FTD (R01 Clinical Trial Not Allowed): This funding opportunity announcement invites research on the mechanism(s) by which abnormal proteins spread throughout the nervous systems of patients with Frontotemporal Dementia and/or Lewy Body Dementia. Applications that move beyond a focus on one mechanisms of spread to consider how spreading might proceed in the context of multiple proteinopathies, multiple cell/circuit types, and multiple pathways are of particular interest.

Federal Grant Title:	Mechanisms of Pathological Spread of Abnormal Proteins in LBD and FTD (R01 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-NS-21-006
Type of Funding:	Grant
CFDA Numbers:	93.853, 93.866
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 27th, 2020
Original Application Deadline:	October 27th, 2020
Posted Date:	August 6th, 2020
Creation Date:	August 6th, 2020
Archive Date:	December 2nd, 2020
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	August 6th, 2020

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-006.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Ge...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...; • Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contribution...; • Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging fin...; • NINDS Cooperative Small Business Awards In Translational Research (SBIR/U44); • NINDS Institutional Center Core Grants to Support Neuroscience Research; • Career Development Award to Promote Diversity in Neuroscience Research
More Grants from the National Institutes of Health: • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed); • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required); • Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Olde...; • NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies w...; • Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental S...